PT1133517E - Distribuição intracelular direccionada de compostos através da proteína de choque térmico de 70 kda - Google Patents
Distribuição intracelular direccionada de compostos através da proteína de choque térmico de 70 kda Download PDFInfo
- Publication number
- PT1133517E PT1133517E PT99960422T PT99960422T PT1133517E PT 1133517 E PT1133517 E PT 1133517E PT 99960422 T PT99960422 T PT 99960422T PT 99960422 T PT99960422 T PT 99960422T PT 1133517 E PT1133517 E PT 1133517E
- Authority
- PT
- Portugal
- Prior art keywords
- intranuclear
- compounds
- heat shock
- shock protein
- targeted delivery
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10987298P | 1998-11-24 | 1998-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1133517E true PT1133517E (pt) | 2009-08-12 |
Family
ID=22330008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99960422T PT1133517E (pt) | 1998-11-24 | 1999-11-17 | Distribuição intracelular direccionada de compostos através da proteína de choque térmico de 70 kda |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1133517B1 (pt) |
JP (1) | JP4892132B2 (pt) |
AU (1) | AU760081B2 (pt) |
CA (1) | CA2352286C (pt) |
CY (1) | CY1110350T1 (pt) |
DE (1) | DE69941156D1 (pt) |
DK (1) | DK1133517T3 (pt) |
ES (1) | ES2327986T3 (pt) |
PT (1) | PT1133517E (pt) |
WO (1) | WO2000031113A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002212236A1 (en) * | 2000-09-13 | 2002-03-26 | Gabriele Multhoff | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
WO2003082346A1 (fr) * | 2002-04-02 | 2003-10-09 | 'asgl-Farmatsevticheskie Innovatsii', Zakrytoe Aktsionernoe Obschestvo | Proteine chimerique recombinante servant a l'administration ciblee d'adn dans des cellules cibles eucaryotes |
US7575738B2 (en) * | 2004-08-13 | 2009-08-18 | General Electric Company | Heat shock protein as a targeting agent for endothelium-specific in vivo transduction |
US8071533B2 (en) | 2006-03-20 | 2011-12-06 | University Of Medicine And Dentistry Of New Jersey | Compositions and methods for modulating store-operated calcium entry |
JP2010538655A (ja) * | 2007-09-12 | 2010-12-16 | アナフォア インコーポレイテッド | 自己免疫疾患についてのhsp70に基づく治療 |
US8999919B2 (en) | 2008-10-22 | 2015-04-07 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the interaction between CFTR and CAL |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
CN107098958B (zh) | 2010-03-26 | 2021-11-05 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
PL2643468T3 (pl) * | 2010-11-22 | 2018-11-30 | Amicus Therapeutics, Inc. | Nowe sekwencje sygnałowe do poprawy ekspresji białek i wydzielania ekombinowanych enzymów i innych białek |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
JP6368308B2 (ja) | 2012-09-07 | 2018-08-01 | トラスティーズ・オブ・ダートマス・カレッジ | 癌の診断および治療のためのvista調節剤 |
DK3087098T3 (da) | 2013-12-24 | 2020-06-08 | Janssen Pharmaceutica Nv | Anti-Vista-antistoffer og -fragmenter |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
CA2951885C (en) | 2014-06-11 | 2023-07-04 | Kathy A. Green | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
EP3277804A1 (en) | 2015-03-31 | 2018-02-07 | Université Pierre et Marie Curie - Paris 6 (UPMC) | Pro-apoptotic set and pp2a peptides |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
TW202216201A (zh) | 2016-02-12 | 2022-05-01 | 比利時商楊森製藥公司 | 抗vista抗體及片段、其用途及鑑定其之方法 |
CN117562992A (zh) | 2016-04-15 | 2024-02-20 | 伊穆奈克斯特股份有限公司 | 抗人vista抗体及其用途 |
CA3115944A1 (en) | 2018-10-10 | 2020-04-16 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08510756A (ja) * | 1993-06-04 | 1996-11-12 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | ストレス蛋白質とその使用 |
ATE318899T1 (de) * | 1996-11-26 | 2006-03-15 | Stressgen Biotechnologies Corp | Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort |
-
1999
- 1999-11-17 CA CA2352286A patent/CA2352286C/en not_active Expired - Fee Related
- 1999-11-17 DK DK99960422T patent/DK1133517T3/da active
- 1999-11-17 ES ES99960422T patent/ES2327986T3/es not_active Expired - Lifetime
- 1999-11-17 AU AU17314/00A patent/AU760081B2/en not_active Ceased
- 1999-11-17 JP JP2000583940A patent/JP4892132B2/ja not_active Expired - Fee Related
- 1999-11-17 EP EP99960422A patent/EP1133517B1/en not_active Expired - Lifetime
- 1999-11-17 WO PCT/US1999/027244 patent/WO2000031113A1/en active IP Right Grant
- 1999-11-17 PT PT99960422T patent/PT1133517E/pt unknown
- 1999-11-17 DE DE69941156T patent/DE69941156D1/de not_active Expired - Lifetime
-
2009
- 2009-09-21 CY CY20091100975T patent/CY1110350T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK1133517T3 (da) | 2009-11-23 |
ES2327986T3 (es) | 2009-11-05 |
EP1133517A4 (en) | 2003-01-08 |
DE69941156D1 (de) | 2009-09-03 |
EP1133517A1 (en) | 2001-09-19 |
CA2352286A1 (en) | 2000-06-02 |
EP1133517B1 (en) | 2009-07-22 |
AU1731400A (en) | 2000-06-13 |
WO2000031113A1 (en) | 2000-06-02 |
JP4892132B2 (ja) | 2012-03-07 |
AU760081B2 (en) | 2003-05-08 |
CA2352286C (en) | 2011-07-12 |
CY1110350T1 (el) | 2015-04-29 |
JP2002530426A (ja) | 2002-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1133517E (pt) | Distribuição intracelular direccionada de compostos através da proteína de choque térmico de 70 kda | |
HUP0203506A3 (en) | Modified peptides as therapeutic agents | |
ZA989461B (en) | Methods and compositions for the treatment of autoimmune disease using heat shock proteins | |
EP1017379A4 (en) | THERAPEUTIC COMPOSITIONS | |
HUP0004412A3 (en) | Use of heterocyclic vinylethers for the preparation of pharmaceutical compositions treating neurological disorders | |
GB2326924B (en) | Adjustable shock absorber | |
IL137616A0 (en) | Variants of vegf-a | |
HUP0100472A3 (en) | Novel amines as pharmaceutical agents | |
PL340254A1 (en) | Derivatives of pleuromutillin as antimicrobial agents | |
HU9802310D0 (en) | Amide derivative | |
NO982473D0 (no) | 5'-Deoksy-cytidinderivater | |
ZA200204635B (en) | Fragments and antagonists of heat shock protein 60. | |
GB9930443D0 (en) | Novel use of heat shock proteins | |
EP1037631A4 (en) | HETEROCYCLIC CATIONIC FATS | |
GB9926529D0 (en) | Targeting agents | |
PL337181A1 (en) | Novel salt | |
EP1003502A4 (en) | ENANTIOMERS OF 4- (CYANOIMINO) - (1,2,2-TRIMETHYLPROPYL) AMINO] METHYL] AMINO] BENZONITRIL | |
HUP0004667A3 (en) | Novel optically active aminopentane derivative | |
EP1079845A4 (en) | NEW THERAPEUTIC SUBSTANCES FOR MACROMOLECULAR STRUCTURES | |
IL150113A0 (en) | Fragments and antagonists of heat shock protein 60 | |
GB9705989D0 (en) | Therapeutic composition | |
GB9817226D0 (en) | Novel use of heat shock proteins | |
GB9920162D0 (en) | Formamide compounds as therapeutic agents | |
FR2777432B1 (fr) | Boitier de maquillage des cils de l'oeil | |
TW331175U (en) | Glass pulverizer of rap type |